Company: DHR
Filing Date: 2025-02-20
Form Type: 10-K
Source: 0000313616-25-000043
Chunk: 19

Company: DANAHER CORP /DE/
Filing Date: 2025-02-20
Form: 10-K
Item: Item 8
Chunk 19
---
 including amounts applicable to each line, and significant terms and conditions of the transactions including commitments and contingencies.  The Company prospectively adopted the ASU effective January 1, 2022 and applied the disclosure guidance to all transactions within the scope of the ASU that were reflected in the financial statements at the date of initial application and new transactions that are entered into subsequent to the date of initial application.  The Company accounts for the government assistance transactions by analogy to the grant accounting model in International Accounting Standards 20, Accounting for Government Grants and Disclosure of Government Assistance.The Company receives various forms of government assistance, primarily through grants related to the development of new products and the expansion of production capacity.  During 2021, certain agencies of the U.S. government, including the Biomedical Advanced Research and Development Authority (“BARDA”) within the U.S. Department of Health and Human Services, agreed to finance an expansion of production capacity related to chromatography, liquid cell culture media, buffers and cell culture powder media and single-use consumables at certain of the Company’s Biotechnology businesses and the development of diagnostics testing technologies and the expansion of testing production capacity at certain of the Company’s Diagnostics businesses.  The Company’s businesses may enter into similar agreements in the future.  In consideration of this financing, the U.S. government has certain rights, including rights with respect to the allocation of certain of the incremental production capacity associated with such expansion and/or rights in intellectual property produced with its financial assistance.  The amount awarded pursuant to these grants in 2021 totaled $568 million and is being paid over periods ranging from one year to four years.  In 2024, 2023 and 2022, the Company recorded amounts related to these grants and other government assistance that offset operating expenses of $43 million, $51 million and $49 million, respectively, and purchases of property, plant and equipment of $198 million, $136 million and $87 million, respectively.  Property, plant and equipment purchased using funds provided by governments are recorded net of government assistance. 

65

In June 2022, the FASB issued ASU No. 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions.  The ASU clarifies the guidance in ASC 820, Fair Value Measurement, related to the measurement of the fair value of an equity security subject to contractual sale restrictions and introduces disclosure requirements related to such equity securities.  The Company early adopted the ASU effective July 1,